TargetMol

Floxuridine

Product Code:
 
TAR-T0964
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0964-50mg50mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0964-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0964-100mg100mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0964-200mg200mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0964-500mg500mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Floxuridine is an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity.
CAS:
50-91-9
Formula:
C9H11FN2O5
Molecular Weight:
246.194
Pathway:
Microbiology/Virology; Apoptosis; ; DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.9996
SMILES:
OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O
Target:
Apoptosis; Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; Antibacterial; HSV

References

1. Tsume Y, et al. Mol Pharm, 2008, 5(5), 717-727. 2. Mini E, et al. Cancer Treat Rep, 1987, 71(4), 381-389. 3. Shin HC, et al. Biol Pharm Bull, 2006, 29(2), 247-252. 4. Khaw PT, et al. Arch Ophthalmol, 1992, 110(8), 1150-1154. 5. Power DG, et al. Mol Cancer Ther, 2009, 8(5), 12015-1025.